OncoMatch/Clinical Trials/NCT07234162
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Is NCT07234162 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for peripheral t-cell lymphoma.
Treatment: Golidocitinib · Chidamide · Pralatrexate · Gemcitabine · Belinostat — This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard systemic therapies
Progressed on, were refractory to or intolerant to at least one line of prior standard systemic therapies assessed by investigator
Lab requirements
Blood counts
Adequate bone marrow reserve
Kidney function
Adequate organ system functions
Liver function
Adequate organ system functions
Adequate bone marrow reserve and organ system functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify